The latest generation of treatments for hepatitis C virus (HCV), direct-acting antivirals (DAAs), have been hailed for their ability to wipe out the disease in most patients. And because they have fewer side effects than traditionally used interferons, they promise to be a safer option for older patients.
However, the late-stage trials of those products largely excluded patients over 70 years of age, leaving physicians with virtually no data to answer a pressing question: Should age be a